Demographics, Clinical Characteristics and Outcomes in Resected Non-Small Cell Lung Cancer Patients Receiving Immunotherapy in Europe and Canada

Sponsor
Bristol-Myers Squibb
Study ID
NCT07718139
Status
Active Not Recruiting

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • nivolumab — BIOLOGICAL
    As per product label
  • pembrolizumab — BIOLOGICAL
    As per product label
  • durvalumab — BIOLOGICAL
    As per product label

Study Details

This study uses existing medical records to better understand how immunotherapy is used in people in Europe and Canada with non-small cell lung cancer (NSCLC) who undergo surgery. It looks at participant characteristics, treatments received before and after surgery, and outcomes such as survival.

Key Dates

First listed
Jul 21, 2026
Start date
Feb 28, 2026
Status verified
Jul 2026
Primary completion
Sep 30, 2026
Completion
Mar 31, 2027

Study Design

Enrollment
300 participants (estimated)

Arms

  • Arm: Neoadjuvant Phase Only
    Participants with resected non-small-cell lung cancer (NSCLC) stage IIA-IIIB who received neoadjuvant immunotherapy prior to surgery but did not initiate adjuvant immunotherapy post-surgery.
  • Arm: Perioperative Immunotherapy
    Participants with resected non-small-cell lung cancer (NSCLC) stage IIA-IIIB who received immunotherapy before surgery and continued the same immunotherapy after surgery (adjuvant phase).

Primary Outcome Measure

Number of participants with pathological complete response after neoadjuvant immunotherapy and surgical resection. [ Time Frame: Up to 14 months ]

Find similar trials

Nationwide
Lung cancer trialsOncology trialsLung oncology trialsLung disease trials

Related Studies